Last week, the Journal of Translational Medicine published a report on the increase in R&D productivity in the industry. The article published the results of analyses of pharmaceutical industry data for the past decade. Dr. Luca Pani, VP Regulatory Strategy and Market Access Innovation was a co-author of the paper.
The authors analyzed data from more than 50,000 pharmaceutical projects spanning 27 years alongside data on sales, patents, and institutional involvement. The analyses identified several significant findings:
- A trend towards high uncertainty/high potential indications such as oncology
- Attrition rates are decreasing at all stages of clinical development
- The time to identify projects to discontinue is decreasing
- The number of projects focused on advanced therapies is growing
- Biotech companies have reached a level of productivity on par with large pharmaceutical companies